Osimertinib-Induced Cardiotoxicity

This publication has 23 references indexed in Scilit:

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2011
• Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
  Journal of Clinical Oncology, 2011
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
  Journal of Clinical Investigation, 2007
• Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
  BMC Cancer, 2007
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• The reporting odds ratio and its advantages over the proportional reporting ratio
  Pharmacoepidemiology and Drug Safety, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004